Annual CFO
-$92.17 M
-$65.39 M-244.27%
December 31, 2023
Summary
- As of February 12, 2025, PSTX annual cash flow from operations is -$92.17 million, with the most recent change of -$65.39 million (-244.27%) on December 31, 2023.
- During the last 3 years, PSTX annual CFO has risen by +$21.16 million (+18.67%).
Performance
PSTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFO
-$9.59 M
-$48.04 M-124.95%
September 30, 2024
Summary
- As of February 12, 2025, PSTX quarterly cash flow from operations is -$9.59 million, with the most recent change of -$48.04 million (-124.95%) on September 30, 2024.
- Over the past year, PSTX quarterly CFO has dropped by -$48.04 million (-124.95%).
Performance
PSTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFO
-$15.02 M
-$17.48 M-710.94%
September 30, 2024
Summary
- As of February 12, 2025, PSTX TTM cash flow from operations is -$15.02 million, with the most recent change of -$17.48 million (-710.94%) on September 30, 2024.
- Over the past year, PSTX TTM CFO has dropped by -$17.48 million (-710.94%).
Performance
PSTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
PSTX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -244.3% | -125.0% | -710.9% |
| 3 y3 years | +18.7% | +76.5% | +89.4% |
| 5 y5 years | -142.5% | +50.0% | +76.7% |
PSTX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | +244.3% | +11.3% | -115.5% | +435.0% | -710.9% | +721.8% |
| 5 y | 5-year | +244.3% | +23.0% | -115.5% | +435.0% | -710.9% | +840.8% |
| alltime | all time | +306.1% | +23.0% | -115.5% | +435.0% | -710.9% | +840.8% |
Poseida Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.59 M(-125.0%) | -$15.02 M(-710.9%) |
| Jun 2024 | - | $38.45 M(-354.0%) | $2.46 M(-103.5%) |
| Mar 2024 | - | -$15.13 M(-47.3%) | -$69.30 M(-24.8%) |
| Dec 2023 | -$92.17 M(+244.3%) | -$28.74 M(-464.4%) | -$92.17 M(+51.0%) |
| Sep 2023 | - | $7.89 M(-123.7%) | -$61.02 M(+768.0%) |
| Jun 2023 | - | -$33.31 M(-12.4%) | -$7.03 M(-47.7%) |
| Mar 2023 | - | -$38.01 M(-1681.6%) | -$13.45 M(-49.7%) |
| Dec 2022 | -$26.77 M(-73.9%) | $2.40 M(-96.1%) | -$26.77 M(+29.3%) |
| Sep 2022 | - | $61.88 M(-255.8%) | -$20.70 M(-83.2%) |
| Jun 2022 | - | -$39.73 M(-22.6%) | -$123.45 M(+7.5%) |
| Mar 2022 | - | -$51.32 M(-705.7%) | -$114.81 M(+12.0%) |
| Dec 2021 | -$102.54 M | $8.47 M(-120.7%) | -$102.54 M(-27.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$40.87 M(+31.5%) | -$141.33 M(+8.9%) |
| Jun 2021 | - | -$31.09 M(-20.4%) | -$129.79 M(+0.2%) |
| Mar 2021 | - | -$39.06 M(+28.8%) | -$129.50 M(+14.3%) |
| Dec 2020 | -$113.33 M(+75.7%) | -$30.32 M(+3.4%) | -$113.33 M(+13.8%) |
| Sep 2020 | - | -$29.33 M(-4.8%) | -$99.58 M(+11.4%) |
| Jun 2020 | - | -$30.80 M(+34.6%) | -$89.42 M(+22.9%) |
| Mar 2020 | - | -$22.89 M(+38.2%) | -$72.74 M(+12.7%) |
| Dec 2019 | -$64.52 M(+69.7%) | -$16.56 M(-13.6%) | -$64.52 M(+34.5%) |
| Sep 2019 | - | -$19.17 M(+35.8%) | -$47.95 M(+66.6%) |
| Jun 2019 | - | -$14.12 M(-3.7%) | -$28.78 M(+96.3%) |
| Mar 2019 | - | -$14.66 M | -$14.66 M |
| Dec 2018 | -$38.01 M(+67.5%) | - | - |
| Dec 2017 | -$22.70 M | - | - |
FAQ
- What is Poseida Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Poseida Therapeutics?
- What is Poseida Therapeutics annual CFO year-on-year change?
- What is Poseida Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Poseida Therapeutics?
- What is Poseida Therapeutics quarterly CFO year-on-year change?
- What is Poseida Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Poseida Therapeutics?
- What is Poseida Therapeutics TTM CFO year-on-year change?
What is Poseida Therapeutics annual cash flow from operations?
The current annual CFO of PSTX is -$92.17 M
What is the all time high annual CFO for Poseida Therapeutics?
Poseida Therapeutics all-time high annual cash flow from operations is -$22.70 M
What is Poseida Therapeutics annual CFO year-on-year change?
Over the past year, PSTX annual cash flow from operations has changed by -$65.39 M (-244.27%)
What is Poseida Therapeutics quarterly cash flow from operations?
The current quarterly CFO of PSTX is -$9.59 M
What is the all time high quarterly CFO for Poseida Therapeutics?
Poseida Therapeutics all-time high quarterly cash flow from operations is $61.88 M
What is Poseida Therapeutics quarterly CFO year-on-year change?
Over the past year, PSTX quarterly cash flow from operations has changed by -$48.04 M (-124.95%)
What is Poseida Therapeutics TTM cash flow from operations?
The current TTM CFO of PSTX is -$15.02 M
What is the all time high TTM CFO for Poseida Therapeutics?
Poseida Therapeutics all-time high TTM cash flow from operations is $2.46 M
What is Poseida Therapeutics TTM CFO year-on-year change?
Over the past year, PSTX TTM cash flow from operations has changed by -$17.48 M (-710.94%)